Related Experiment Video
Updated: Aug 8, 2026

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions
Published on: June 28, 2018
The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a
1Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
Binding of a hormone agonist to a steroid receptor leads to the dissociation of heat shock proteins, dimerization, specific DNA binding, and target gene activation. Although the progesterone antagonist RU486 can induce most of these events, it fails to activate human progesterone receptor (hPR)-dependent transcription. We have previously demonstrated that a conformational change is a key event leading to receptor activation. The major conformational distinction between hormone- and antihormone-bound receptors occurs within the C-terminal portion of the molecule. Furthermore, hPR mutants lacking the C terminus become transcriptionally active in the presence of RU486. These results suggest that the C terminus contains a repressor domain that inhibits the transcriptional activity of the RU486-bound hPR. In this study, we have defined a 12 amino acid (12AA) region in the C terminus of hPR that is necessary and sufficient for the repressor function when fused to the C-terminal truncated hPR or to the GAL4 DNA-binding domain. Mutations in the 12AA domain (aa 917-928) generate an hPR that is active in the presence of RU486. Furthermore, overexpression of the 12AA peptide activates the RU486-bound wild-type hPR without affecting progesterone-dependent activation. These results suggest that association of the 12AA repressor region with a corepressor might inactivate hPR activity when it is bound to RU486. We propose that binding of a hormone agonist to the receptor changes its conformation in the ligand-binding domain so that association with coactivator is promoted and activation of target gene occurs.
Insights
A 12-amino acid region in the human progesterone receptor (hPR) C-terminus acts as a repressor, inhibiting transcription with antagonists like RU486. Mutations or overexpression of this domain activate the receptor.
Area of Science:
- Molecular Endocrinology
- Steroid Receptor Signaling
- Gene Transcription Regulation
Background:
- Hormone agonists activate steroid receptors via conformational changes, DNA binding, and gene activation.
- The progesterone antagonist RU486 induces most receptor activation steps but fails to trigger transcription of human progesterone receptor (hPR)-dependent genes.
- Previous studies indicated a key conformational change, particularly in the C-terminus, differentiates hormone- and antihormone-bound receptors.
Purpose of the Study:
- To identify the specific region within the hPR C-terminus responsible for repressing transcriptional activity in the presence of the antagonist RU486.
- To investigate the functional role of this identified repressor domain in regulating hPR activity.
Main Methods:
- Construction and analysis of hPR mutants lacking the C-terminus.
- Fusion of truncated hPR or GAL4 DNA-binding domain with specific C-terminal regions.
- Site-directed mutagenesis of the identified 12-amino acid (12AA) domain (aa 917-928).
- Overexpression studies of the 12AA peptide in wild-type hPR.
Main Results:
- A 12AA region (aa 917-928) in the hPR C-terminus was identified as necessary and sufficient for repressor function.
- Mutations within this 12AA domain rendered the hPR transcriptionally active in the presence of RU486.
- Overexpression of the 12AA peptide activated RU486-bound wild-type hPR without affecting progesterone-mediated activation.
- These findings suggest the 12AA region may recruit corepressors to inhibit hPR activity upon RU486 binding.
Conclusions:
- The C-terminal 12AA region of hPR functions as a potent repressor domain, specifically inhibiting transcription when the receptor is bound by antagonists like RU486.
- This repressor domain's activity appears to be modulated by corepressor association, influencing the transcriptional outcome.
- Understanding this repressor mechanism provides insights into differential activation by agonists versus antagonists and potential therapeutic targeting.
More Related Videos
10:28Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
Related Concept Videos
RNA Polymerase II Accessory Proteins
The Eukaryotic Promoter Region
Co-activators and Co-repressors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors